Correlation Between Xbrane Biopharma and Swedish Orphan

Can any of the company-specific risk be diversified away by investing in both Xbrane Biopharma and Swedish Orphan at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xbrane Biopharma and Swedish Orphan into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Xbrane Biopharma AB and Swedish Orphan Biovitrum, you can compare the effects of market volatilities on Xbrane Biopharma and Swedish Orphan and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xbrane Biopharma with a short position of Swedish Orphan. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xbrane Biopharma and Swedish Orphan.

Diversification Opportunities for Xbrane Biopharma and Swedish Orphan

-0.03

Correlation Coefficient

Xbrane Biopharma  Swedish Orphan

Good diversification

The 3 months correlation between Xbrane and Swedish is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Xbrane Biopharma AB and Swedish Orphan Biovitrum in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Swedish Orphan Biovitrum and Xbrane Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xbrane Biopharma AB are associated (or correlated) with Swedish Orphan. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Swedish Orphan Biovitrum has no effect on the direction of Xbrane Biopharma i.e., Xbrane Biopharma and Swedish Orphan go up and down completely randomly.

Pair Corralation between Xbrane Biopharma and Swedish Orphan

Assuming the 90 days trading horizon Xbrane Biopharma AB is expected to generate 4.94 times more return on investment than Swedish Orphan. However, Xbrane Biopharma is 4.94 times more volatile than Swedish Orphan Biovitrum. It trades about 0.15 of its potential returns per unit of risk. Swedish Orphan Biovitrum is currently generating about -0.09 per unit of risk. If you would invest  16.00  in Xbrane Biopharma AB on December 24, 2024 and sell it today you would earn a total of  12.00  from holding Xbrane Biopharma AB or generate 75.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Xbrane Biopharma AB  vs.  Swedish Orphan Biovitrum

Xbrane Biopharma

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Xbrane Biopharma AB are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Xbrane Biopharma sustained solid returns over the last few months and may actually be approaching a breakup point.

Swedish Orphan Biovitrum

Risk-Adjusted Performance

Very Weak

Over the last 90 days Swedish Orphan Biovitrum has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Xbrane Biopharma and Swedish Orphan

The main advantage of trading using opposite Xbrane Biopharma and Swedish Orphan positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xbrane Biopharma position performs unexpectedly, Swedish Orphan can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Swedish Orphan will offset losses from the drop in Swedish Orphan's long position.

The idea behind Xbrane Biopharma AB and Swedish Orphan Biovitrum pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.